BioLineRx (ADR) (BLRX)
Builds oncology assets around APHEXDA royalties and GLIX1 clinical development.
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing GLIX1 achieved potent antitumor activity in TMZ-resistant patient-derived xenograft (PDX) GBM in vivo model - - Announced additional data demonstrating strong synergistic effect between GLIX1 and PARP inhibitor in patient-derived HR-proficient ovarian cancer xenograft model - - Management to host conference call today, August 31, at 8:30 am EDT - TEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of $2.78 per ADS (or per ADS equivalent) through a registered direct offering.
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place October 23rd to October 27th in Madrid, Spain.
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer TEL AVIV, Israel and OSLO, Norway, July 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced highly encouraging new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft (PDX) model of ovarian cancer.
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model - - Management to host conference call today, May 27, at 8:30 am EDT - TEL AVIV, Israel, May 27, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update.
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held May 29-June 2, 2026, in Chicago, IL.
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's potential to address the high unmet need for patients with GBM TEL AVIV, Israel and OSLO, Norway, May 19, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced highly encouraging new preclinical data that further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive GBM and other high-grade gliomas.
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the Phase 1 part of the study anticipated in H1 2027 TEL AVIV, Israel, and OSLO, Norway, April 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that the first patient has been dosed in the first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple GBM models, excellent blood-brain barrier penetration and a favorable safety profile in preclinical toxicology studies Study is being conducted by world-leading glioblastoma investigators, led by Dr. Roger Stupp TEL AVIV, Israel, March 26, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma (NCT07464925).
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms - - Management to host conference call today, March 23, at 8:30 am EDT - TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.
BioLineRx (BLRX) Projected to Post Quarterly Earnings on Monday
BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $0.4920 million for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page for
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
BioLineRx to Report 2025 Annual Results on March 23, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24 th, at 8:30 am EST - TEL AVIV, Israel , Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.